scispace - formally typeset
M

Michele Caraglia

Researcher at Seconda Università degli Studi di Napoli

Publications -  562
Citations -  24508

Michele Caraglia is an academic researcher from Seconda Università degli Studi di Napoli. The author has contributed to research in topics: Cancer & Cancer cell. The author has an hindex of 67, co-authored 525 publications receiving 20615 citations. Previous affiliations of Michele Caraglia include Temple University & Magna Græcia University.

Papers
More filters
Journal ArticleDOI

In vitro anticancer activity of docetaxel-loaded micelles based on poly(ethylene oxide)-poly(epsilon-caprolactone) block copolymers: Do nanocarrier properties have a role?

TL;DR: The results suggest that for a correct interpretation of cytotoxicity of nanocarriers, the evaluation of their behavior in biologically relevant conditions is of utmost importance to select proper systems for further in vivo testing.
Journal ArticleDOI

Alpha-interferon and its effects on signalling pathways within cells.

TL;DR: A reactive mechanism of protection of tumour cells from the apoptosis induced by IFNalpha dependent on the epidermal growth factor-mediated Ras/extracellular signal regulated kinase (Erk) signalling is described, suggesting that the specific disruption of the latter could be a useful approach to potentiate the antitumour activity of IFN alpha against human tumours.
Journal ArticleDOI

Non-thermal effects of electromagnetic fields at mobile phone frequency on the refolding of an intracellular protein: myoglobin.

TL;DR: The data suggest that MW‐EMF could have also biochemical and, consequently, biological effects on eukaryotic cells that are still under investigation, and changes in the structural fluctuation caused by MW perturbation can affect differently the aggregation process that occurs competitively during the protein folding, so representing a potential risk for protein “misfolding.
Journal ArticleDOI

Isoprenylation of intracellular proteins as a new target for the therapy of human neoplasms: preclinical and clinical implications.

TL;DR: The inhibition of isoprenylation is an attractive, but still not completely investigated therapeutic alternative that requires optimization for the translation in the current treatment of neoplasms.